Next Article in Journal
Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound
Next Article in Special Issue
Deregulation of Interferon Signaling in Malignant Cells
Previous Article in Journal
Nitric Oxide Synthase Inhibitors as Antidepressants
Previous Article in Special Issue
Interferons as Therapy for Viral and Neoplastic Diseases: From Panacea to Pariah to Paragon
Open AccessReview

Oromucosal Administration of Interferon to Humans

1
School of Biomedical, Biomolecular and Chemical Sciences, University of Western Australia, 35 Stirling Highway, Crawley WA 6009, Australia
2
Amarillo Biosciences, Inc., 4134 Business Park Drive, Amarillo, TX 79110, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(2), 323-344; https://doi.org/10.3390/ph3020323
Received: 1 December 2009 / Revised: 20 January 2010 / Accepted: 25 January 2010 / Published: 28 January 2010
(This article belongs to the Special Issue Interferons)
The prevailing dogma is that, to be systemically effective, interferon-alpha (IFNα) must be administered in sufficiently high doses to yield functional blood concentrations. Such an approach to IFNa therapy has proven effective in some instances, but high-dose parenteral IFNα therapy has the disadvantage of causing significant adverse events. Mounting evidence suggests that IFNα delivered into the oral cavity in low doses interacts with the oral mucosa in a unique manner to induce systemic host defense mechanisms without IFNα actually entering the circulation, thus reducing the potential for toxic side effects. A better understanding of the applications and potential benefits of this treatment modality are under active investigation. This paper provides a review of the relevant literature on the clinical use of the oromucosal route of administration of interferon, with an emphasis on the treatment of influenza. View Full-Text
Keywords: interferon; oromucosal delivery; influenza; treatment; viral diseases interferon; oromucosal delivery; influenza; treatment; viral diseases
MDPI and ACS Style

Beilharz, M.W.; Cummins, M.J.; Bennett, A.L.; Cummins, J.M. Oromucosal Administration of Interferon to Humans. Pharmaceuticals 2010, 3, 323-344.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop